Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis.

Area of Science:

• Pulmonary Medicine
• Pharmacology
• Clinical Trials

Background:

• Preclinical data suggest inhaled treprostinil has antifibrotic properties beneficial for idiopathic pulmonary fibrosis (IPF).
• Clinical observations support the potential efficacy of inhaled treprostinil in managing IPF.

Purpose of the Study:

• To evaluate the efficacy and safety of inhaled treprostinil versus placebo in patients with IPF.
• To assess the impact of inhaled treprostinil on lung function and clinical outcomes over 52 weeks.

Main Methods:

• Phase 3, double-blind, randomized trial involving 593 IPF patients assigned to inhaled treprostinil or placebo.
• Primary endpoint: change in absolute forced vital capacity (FVC) at 52 weeks.
• Secondary endpoints included clinical worsening, IPF exacerbation, mortality, and changes in FVC percentage, quality of life, and diffusing capacity.

Main Results:

• Inhaled treprostinil demonstrated a median FVC change of -49.9 ml versus -136.4 ml for placebo (difference: 95.6 ml; P<0.001).
• Clinical worsening occurred in 27.2% of the treprostinil group versus 39.0% of the placebo group (HR, 0.71; P=0.02).
• Cough was the most frequent adverse event; discontinuation rates due to adverse events were higher with treprostinil.

Conclusions:

• Inhaled treprostinil was associated with a slower rate of FVC decline in IPF patients over 52 weeks.
• Inhaled treprostinil significantly reduced the incidence of clinical worsening events compared to placebo.
• The study met its primary endpoint, suggesting a potential therapeutic benefit for inhaled treprostinil in IPF management.